Agendia Announces Colorectal Cancer Research Collaboration With Leading Cancer Centers - MD Anderson Cancer Center and Netherlands Cancer Institute

AMSTERDAM, The Netherlands, and IRVINE, California, June 9, 2011
(ots/PRNewswire) --

Agendia, a commercial-stage molecular cancer diagnostics company,
announces today that it has entered into a research collaboration
with The University of Texas MD Anderson Cancer Center, one of the
world's leading cancer centers and whose research program is
considered one of the most productive in the world aimed solely at
cancer, and the Netherlands Cancer Institute (NKI) with the aim of
improving diagnosis and treatment options of colorectal cancer
patients. The work is based on an approach toward integrating several
genomic and proteomic technologies in order to study patterns of gene
and protein expression in cancerous tumors that may, when combined,
provide greater insight into the unique biology of individual
patients' tumors and why patients often have different prognosis and
varied responses to the same treatment.

Colorectal cancer is a leading cause of cancer-related death
worldwide, with more than 1.2 million new cases each year. Though
early detection and better treatment options have resulted in
improved prognoses for many patients, more than half of colorectal
cancer patients still die from the disease. While past researchers
have often looked at just one aspect of the cancer's progression, the
new integrated approach utilized by MD Anderson, NKI and Agendia will
analyze colorectal cancer samples on multiple levels. Specifically
the collaboration will study the active genome (gene expression),
mutation status and protein activation measured in the same sample
and combine results with pathological and clinical data.

"In MD Anderson and NKI we have found not only experts in the
fields of functional genomics, proteomics, and clinical oncology, but
also partners who share our commitment to putting the most effective
tools in the hands of physicians and their patients to simplify
difficult cancer decisions," said Bernhard Sixt, Chief Executive
Officer of Agendia.

In addition to a better understanding of the individual biology,
this collaboration will allow an independent validation of
ColoPrint(R), Agendia's colon cancer recurrence test. Agendia is
currently developing ColoPrint(R), which works by identifying Stage
II colon cancer patients who are either at low risk or at high risk
of experiencing a disease recurrence. As demonstrated in previous
validation studies for Agendia's currently marketed products,
ColoPrint(R), when combined with clinical parameters, has the
potential to provide clinicians with a more reliable means to assist
them in treatment decision-making for patients with Stage II colon
cancer.

"The unique structure of this consortium makes possible the rapid
translation of results from research and discovery to clinical
setting that benefits patients sooner," said Scott Kopetz, MD, PhD,
principal investigator of this research consortium and Assistant
Professor in the Department of Gastrointestinal Medical Oncology at
MD Anderson.

About Agendia

Agendia is an innovative molecular diagnostic company, striving
to develop more effective, individualized treatments within reach of
patients. Building on a genomics platform for tumor gene expression
profiling, the company's tests help physicians more accurately select
a course of cancer treatment for their patients. Agendia markets four
products, with several new genomic tests under development. In
addition, Agendia collaborates with pharmaceutical companies to
develop companion diagnostic tests in the area of oncology. Agendia
is based in Amsterdam, the Netherlands and in Irvine, California. For
more information, please visit http://www.agendia.com.

For further information, please contact:
Agendia
Dr. Bernhard Sixt, President & CEO
Investorrelations@agendia.com
International media and investor enquiries
M:Communications
Mary-Jane Elliott / Emma Thompson
Tel: +44(0)20-7920-2345, E-mail: Agendia@mcomgroup.com
Dutch media enquiries
Huijskens Communications
Ian Bickerton
Tel: +31(0)20-685-5955, E-mail: i.bickerton@huijskens.nl
US Media enquiries
Ricochet Public Relations
Valerie Carter
Tel: +1-202-316-0143, E-mail: vcarter@ricochetpr.com

ots Originaltext: Agendia BV
Im Internet recherchierbar: http://www.presseportal.de

Contact:
.